Investment
Features
FeesSafety
Academy
More
Pluang+

Compare News Corporation Class A Common Stock (NWSA) vs Organon & Co. Common Stock (OGN) Price & Performance

News Corporation Class A Common StockTrade
Organon & Co. Common StockTrade

Price performance (Past 24H)

Key statistics

News Corporation Class A Common Stock vs Organon & Co. Common Stock — how do they compare? News Corporation Class A Common Stock trades at $29.49 (market cap $16.49B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: News Corporation Class A Common Stock is far larger — about 4.6× Organon & Co. Common Stock's market cap, and News Corporation Class A Common Stock pays the higher dividend (0.67%). Which is the better fit depends on your goals — on Pluang, investors hold News Corporation Class A Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.

NWSAOGN
Market Cap
$16.49B$3.62B
Volume
2,643,3782,892,999
Sector
MediaHealth
52-Week High
$31.19$13.81
52-Week Low
$22.40$5.70
Typical Hold Time
6 Days0 Days
Enterprise Value
$17.31B$11.04B
Dividend Yield
0.67%0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

News Corporation Class A Common Stock

News Corporation (NWSA) trades at $29.63, up 0.85% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $32.20. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.35 surpassing the $0.21 expectation. Revenue for 2025 reached $8.45 billion, though net income is projected to decline significantly in 2026. Recent news highlights include the launch of a personalized news AI, 'Hamilton,' and ongoing speculation about a potential re-merger with Fox Corp.

The outlook is cautiously optimistic, supported by strong analyst sentiment and consistent earnings beats. Key opportunities lie in digital real estate and news monetization, while risks include a projected profit margin contraction and broader market volatility. The stock's current valuation, with a P/E of 28.77, suggests growth expectations are already priced in, requiring sustained execution to justify further upside.

Organon & Co. Common Stock

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NWSA

No sentiment data available yet.

OGN
100% Buy0% Sell
Avg holding period · 0 Days

About News Corporation Class A Common Stock

News Corporation operates businesses in news and information services, digital real estate, and book publishing. Its brands include Dow Jones, The Wall Street Journal, HarperCollins, Realtor.com, and realestate.com.au.

Read more on NWSA →

About Organon & Co. Common Stock

Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.

Read more on OGN →